Supergroup【SGP】株式ニュース

AVELOX(R) Monotherapy as Effective as High-Dose Levofloxacin and Ceftriaxone Combination Therapy in Treating Patients With Seve

New Head-To-Head Study Presented at 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) KENILWORTH, N.J., April 7...

Study Shows LEVITRA(R) Treats Erectile Dysfunction Effectively in Men Taking Medications to Lower High Blood Pressure

Clinical trial data showed improvement in erectile function with LEVITRA was unaffected by different classes of anti-hypertensive medication...

Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034

KENILWORTH, N.J., Jan. 30 /PRNewswire-FirstCall/ -- Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted...

Head-To-Head Study Shows More Elderly Patients With Community-Acquired Pneumonia Recovered at Days 3 to 5 With AVELOX(R) (Moxifl

CAPRIE first clinical study to compare fluoroquinolones in elderly population with community-acquired pneumonia KENILWORTH, N.J., Jan. 24...

Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV

ENDURE Study to Assess Low-Dose PEG-INTRON Monotherapy in Helping to Prevent Hepatitis C Disease Progression in Coinfected Patients AMSTERDAM...

Schering-Plough Board of Directors Announces New Election, Governance Measures

KENILWORTH, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Schering-Plough's Board of Directors unanimously agreed to recommend to shareholders that...

Schering-Plough Media Alert: Data on Schering-Plough Anti-Infectives to Be Presented at ICAAC

KENILWORTH, N.J., Dec. 13 /PRNewswire/ -- Important new data on several Schering-Plough anti-infective products and compounds in development...

Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monotherapy and in Combination With PEG-

Results Reported at American Association for the Study of Liver Diseases (AASLD) Meeting SAN FRANCISCO, Nov. 14 /PRNewswire-FirstCall/...

PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates Consistently High Response Rates Across Patient Weight Groups in '

Preliminary Results of Large Canadian Observational Study Presented at American Association for the Study of Liver Diseases (AASLD) Meeting SAN...

Data on Schering-Plough's Oral HCV Protease Inhibitor to be Presented for First Time at American Association for the Study of Li

Final Results of PEG-INTRON(R) Combination Therapy Studies Also Presented KENILWORTH, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Important new data...

TEMODAL (R) After Surgery Significantly Improves Survival in Patients With Newly Diagnosed Glioblastoma Multiforme

Study Presented at European Cancer Conference (ECCO) Shows 18-Month Median and 37% Two-Year Survival in Patients Treated with TEMODAL (R...

Study Shows 12 Weeks of Peginterferon Alfa-2b and Ribavirin Combination Therapy as Effective as 24 Weeks in Certain Hepatitis C

Study Shows 12 Weeks of Peginterferon Alfa-2b and Ribavirin Combination Therapy as Effective as 24 Weeks in Certain Hepatitis C Patients With...

Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in Diverse Patient Populations to Be Presented at 2005 Digestive Diseas

Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in Diverse Patient Populations to Be Presented at 2005 Digestive Disease Week (DDW...

/C O R R E C T I O N -- Schering-Plough Corporation (NYSE: SGP)/

/C O R R E C T I O N -- Schering-Plough Corporation (NYSE: SGP)/ In the correction regarding the news release, Schering-Plough Reports...

/C O R R E C T I O N -- Schering-Plough Corporation (NYSE: SGP)/

/C O R R E C T I O N -- Schering-Plough Corporation (NYSE: SGP)/ In the news release, Schering-Plough Reports Financial Results for 2005...

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Supergroup (SGP)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

SGP ニュース

AVELOX(R) Monotherapy as Effective as High-Dose Levofloxacin and Ceftriaxone Combination Therapy in Treating Patients With Seve

Study Shows LEVITRA(R) Treats Erectile Dysfunction Effectively in Men Taking Medications to Lower High Blood Pressure

Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034

Head-To-Head Study Shows More Elderly Patients With Community-Acquired Pneumonia Recovered at Days 3 to 5 With AVELOX(R) (Moxifl

Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV

Schering-Plough Board of Directors Announces New Election, Governance Measures

Schering-Plough Media Alert: Data on Schering-Plough Anti-Infectives to Be Presented at ICAAC

Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monotherapy and in Combination With PEG-

PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates Consistently High Response Rates Across Patient Weight Groups in '

Data on Schering-Plough's Oral HCV Protease Inhibitor to be Presented for First Time at American Association for the Study of Li

TEMODAL (R) After Surgery Significantly Improves Survival in Patients With Newly Diagnosed Glioblastoma Multiforme

Study Shows 12 Weeks of Peginterferon Alfa-2b and Ribavirin Combination Therapy as Effective as 24 Weeks in Certain Hepatitis C

Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in Diverse Patient Populations to Be Presented at 2005 Digestive Diseas

/C O R R E C T I O N -- Schering-Plough Corporation (NYSE: SGP)/

/C O R R E C T I O N -- Schering-Plough Corporation (NYSE: SGP)/

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Supergroup (SGP) ニュース

Supergroup (SGP)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

SGP ニュース

AVELOX(R) Monotherapy as Effective as High-Dose Levofloxacin and Ceftriaxone Combination Therapy in Treating Patients With Seve

Study Shows LEVITRA(R) Treats Erectile Dysfunction Effectively in Men Taking Medications to Lower High Blood Pressure

Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034

Head-To-Head Study Shows More Elderly Patients With Community-Acquired Pneumonia Recovered at Days 3 to 5 With AVELOX(R) (Moxifl

Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV

Schering-Plough Board of Directors Announces New Election, Governance Measures

Schering-Plough Media Alert: Data on Schering-Plough Anti-Infectives to Be Presented at ICAAC

Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monotherapy and in Combination With PEG-

PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates Consistently High Response Rates Across Patient Weight Groups in '

Data on Schering-Plough's Oral HCV Protease Inhibitor to be Presented for First Time at American Association for the Study of Li

TEMODAL (R) After Surgery Significantly Improves Survival in Patients With Newly Diagnosed Glioblastoma Multiforme

Study Shows 12 Weeks of Peginterferon Alfa-2b and Ribavirin Combination Therapy as Effective as 24 Weeks in Certain Hepatitis C

Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in Diverse Patient Populations to Be Presented at 2005 Digestive Diseas

/C O R R E C T I O N -- Schering-Plough Corporation (NYSE: SGP)/

/C O R R E C T I O N -- Schering-Plough Corporation (NYSE: SGP)/

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手